Lavakumar Karyampudi: Building early-phase CGT infrastructure for translational success
About this episode
Lavakumar Karyampudi discusses the evolution of academic institutions in supporting early-phase CGT trials.
In this episode of the Ori Spotlight Podcast, Jason C. Foster welcomes Lavakumar (Kumar) Karyampudi, Senior Director of Cell Therapies at Moffitt Cancer Center, to discuss how academic institutions are evolving to meet the demands of early-phase CGT trials. Kumar shares how Moffitt is building flexible, end-to-end infrastructure that supports the full development cycle – from translational research to GMP manufacturing. Together, they explore how tighter integration between scientists, clinicians, and operational teams can accelerate first-in-human trials, why academic centres play a crucial role in advancing CGTs, and how the right partnerships can extend institutional capabilities. Connect with Kumar: https://www.linkedin.com/in/lavakumar-karyampudi/
More episodes of Ori Spotlight
- Ken Harris: Why AI and automation are CGT’s next inflection point
- Joe DePinto: Why advanced therapies need a new delivery model
- Jonathan Gluck: A personal account of navigating myeloma and CAR-T therapy
- John Khoury: The CGT developers who adapt new manufacturing techniques early will lead later
- Warner Biddle: Building a commercial model for CAR-T in autoimmune care
- Henrik Andersen: How smart planning helps CGT scale further, faster
Explore listener stats, chart rankings, contacts and more on the Ori Spotlight podcast page.